|Articles|October 1, 1999

The Appropriate Use of Antibiotic Therapy
Volume 5
Issue 15 Suppl

Intramuscular Antibiotics in the Treatment of Pediatric Upper Respiratory Tract Infection

Author(s)Emily J. Chang, MD, S. Michael March, MD

Download PDF: Intramuscular Antibiotics in the Treatment of Pediatric Upper Respiratory Tract Infection

Articles in this issue

almost 27 years ago

Article

Participating Faculty

almost 27 years ago

Article

Introduction

almost 27 years ago

Article

Assessing the Risk of Adverse Reactions to Intramuscular Benzathine Penicillin G

almost 27 years ago

Article

Diagnosis and Management of Group A Streptococcal Pharyngitis: A Practice Guideline

almost 27 years ago

Article

Drug Resistance and the Treatment of Upper Respiratory Infections

almost 27 years ago

Article

CME Quiz

almost 27 years ago

Article

Bibliography

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Intramuscular Antibiotics in the Treatment of Pediatric Upper Respiratory Tract Infection

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

Fifth Death Confirmed in NYC Legionnaires' Outbreak

Small Workflow Changes Close Big Gaps in CKM Screening

Pirtobrutinib Plus Venetoclax-Rituximab Cuts CLL Progression 45%

Obesity, Insulin Resistance, and the Silent Progression of MASH: A Hepatologist's Perspective